Price$22.30+0.11 (+0.47%)
01:30 PM07:45 PM
News · 26 weeks52-50%
2026-01-182026-07-12
Mix3290d
- Insider14(44%)
- Other12(38%)
- SEC Filings5(16%)
- Analyst1(3%)
Latest news
25 items- INSIDERCHIEF BUSINESS OFFICER Horn Kinney exercised 1,092 shares at a strike of $12.92 and sold $27,300 worth of shares (1,092 units at $25.00) as part of a pre-agreed trading plan (SEC Form 4)4 - Immunome Inc. (0001472012) (Issuer)
- PRImmunome Announces U.S. FDA Acceptance of New Drug Application for Varegacestat for the Treatment of Adults with Desmoid TumorsPDUFA target action date set for April 28, 2027 Varegacestat could provide a meaningful new oral treatment option for adults with desmoid tumors if approved Immunome, Inc. (NASDAQ:IMNM), a biotechnology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced the U.S. Food and Drug Administration (FDA or the Agency) has accepted its New Drug Application (NDA) for varegacestat, an investigational, oral, once-daily gamma secretase inhibitor (GSI), for the treatment of adults with desmoid tumors. The FDA assigned a Prescription Drug User Fee Act (PDUFA) target action date of April 28, 2027. "The FDA’s acceptance of our NDA for varegac
- INSIDERDirector Barchas Isaac sold $2,412,522 worth of shares (100,000 units at $24.13) as part of a pre-agreed trading plan (SEC Form 4)4 - Immunome Inc. (0001472012) (Issuer)
- INSIDERChief Medical Officer Lechleider Robert exercised 55,000 shares at a strike of $8.73 and sold $1,244,331 worth of shares (55,000 units at $22.62) as part of a pre-agreed trading plan (SEC Form 4)4 - Immunome Inc. (0001472012) (Issuer)
- PRImmunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Immunome, Inc. (the "Company") (NASDAQ:IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on July 1, 2026, the Compensation Committee of the Company’s Board of Directors (the "Compensation Committee") granted inducement awards consisting of non-statutory stock options to purchase an aggregate of 344,000 shares of common stock to seventeen new employees under the Company’s 2024 Inducement Plan. The Compensation Committee approved the stock options as an inducement material to such employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option has an exercise price per share equal
- INSIDERDirector Barchas Isaac sold $4,393,024 worth of shares (201,050 units at $21.85) as part of a pre-agreed trading plan (SEC Form 4)4 - Immunome Inc. (0001472012) (Issuer)
- INSIDERChief Medical Officer Lechleider Robert exercised 55,000 shares at a strike of $8.73 and sold $1,091,662 worth of shares (55,000 units at $19.85) as part of a pre-agreed trading plan (SEC Form 4)4 - Immunome Inc. (0001472012) (Issuer)
- INSIDERChief Financial Officer Rosett Max sold $1,093,800 worth of shares (60,000 units at $18.23) as part of a pre-agreed trading plan and exercised 60,000 shares at a strike of $1.05 (SEC Form 4)4 - Immunome Inc. (0001472012) (Issuer)
- INSIDERSEC Form 4 filed by Director Swain Sandra M4 - Immunome Inc. (0001472012) (Issuer)
- INSIDERSEC Form 4 filed by Director Wagenheim Philip4 - Immunome Inc. (0001472012) (Issuer)
- INSIDERSEC Form 4 filed by Director Bienaime Jean Jacques4 - Immunome Inc. (0001472012) (Issuer)
- INSIDERSEC Form 4 filed by Director Boylan James P4 - Immunome Inc. (0001472012) (Issuer)
- INSIDERSEC Form 4 filed by Director Barchas Isaac4 - Immunome Inc. (0001472012) (Issuer)
- INSIDERSEC Form 4 filed by Director Schafer Carol4 - Immunome Inc. (0001472012) (Issuer)
- SECImmunome Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Immunome Inc. (0001472012) (Filer)
- PRImmunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-1617, a Potential First-in-Class ADC, in Patients with Advanced Solid TumorsIM-1617 is a potential first-in-class solid tumor antibody-drug conjugate (ADC) that incorporates HC74, Immunome's proprietary topoisomerase I (TOP1) inhibitor payload Immunome ADC pipeline momentum anticipated to continue with investigational new drug (IND) submissions for IM-1340 and IM-1335 planned for mid- and late 2026, respectively Immunome, Inc. (NASDAQ:IMNM), a biotechnology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced that the first patient has been dosed in the Phase 1, first-in-human trial of IM-1617, a potential first-in-class ADC directed at an undisclosed solid tumor target and incorporating HC74, Immunome's
- INSIDERDirector Bienaime Jean Jacques sold $203,820 worth of shares (10,500 units at $19.41) and bought $204,260 worth of shares (10,500 units at $19.45) (SEC Form 4)4 - Immunome Inc. (0001472012) (Issuer)
- PRImmunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Immunome, Inc. (the "Company") (NASDAQ:IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on June 1, 2026, the Compensation Committee of the Company's Board of Directors (the "Compensation Committee") granted inducement awards consisting of non-statutory stock options to purchase an aggregate of 353,000 shares of common stock to twenty new employees under the Company's 2024 Inducement Plan. The Compensation Committee approved the stock options as an inducement material to such employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option has an exercise price per share equal to
- PRImmunome Announces Detailed Phase 3 RINGSIDE Data for Varegacestat in Adults with Progressing Desmoid Tumors at the 2026 ASCO Annual MeetingVaregacestat treatment resulted in statistically significant improvements in primary and all key secondary efficacy endpoints Varegacestat demonstrated statistically significant improvement in worst pain intensity at week 12, with a clinically significant difference observed as early as the first evaluation at week 4 Progression-free survival benefit was consistent across prespecified patient subgroups, including tumor location, baseline tumor size, patient age and prior systemic desmoid tumor therapy New Drug Application (NDA) for varegacestat submitted to the U.S. Food and Drug Administration (FDA) in April 2026, with Marketing Authorization Application (MAA) submission to the E
- ANALYSTBarclays initiated coverage on Immunome with a new price targetBarclays initiated coverage of Immunome with a rating of Overweight and set a new price target of $36.00
- PRImmunome to Present at the Goldman Sachs 47th Annual Global Healthcare ConferenceImmunome, Inc. (NASDAQ:IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that members of Immunome's management will present at the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026, at 10:40 a.m. EDT. Interested parties can access the live audio webcast for this conference from the Investor Relations section of the company's website at www.immunome.com. The webcast replay will be available after the conclusion of the live presentation for approximately 30 days. About Immunome, Inc. Immunome is a clinical-stage targeted oncology company committed to developing first-in-class and best-in-
- INSIDERDirector Bienaime Jean Jacques bought $103,500 worth of shares (5,000 units at $20.70), increasing direct ownership by 13% to 43,415 units (SEC Form 4)4 - Immunome Inc. (0001472012) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Immunome Inc.SCHEDULE 13G/A - Immunome Inc. (0001472012) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Immunome Inc.SCHEDULE 13G/A - Immunome Inc. (0001472012) (Subject)
- SECSEC Form 10-Q filed by Immunome Inc.10-Q - Immunome Inc. (0001472012) (Filer)
IMNM FAQ
7 questionsWhat does Immunome Inc. do?
Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.Where does IMNM stock trade?
Immunome Inc. (IMNM) is listed on NASDAQ.What sector and industry is IMNM in?
Immunome Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Immunome Inc. go public?
Immunome Inc. (IMNM) completed its IPO in 2020.What are analysts saying about IMNM?
Immunome Inc. has had 8 recent analyst actions on file. The most recent action was from Barclays: Overweight with a $3600.00 price target on 2026-05-28. Recent price targets range from $2300.00 to $4000.00.What companies are similar to IMNM?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare IMNM side-by-side with any of them on Quantisnow.How can I track IMNM on Quantisnow?
Quantisnow aggregates Immunome Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow IMNM to receive live email and push alerts on every new disclosure.